A clinical-stage biotechnology company

PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.


PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is in Phase Ia/b clinical trials for the treatment of advanced solid tumors in partnership with Institut Curie and Gustave Roussy, two leading European cancer centers. The study is also conducted at François Baclesse center.


Backed by international investors

PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, Anaxago, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and by Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).

Our partners

logo seventure
Logo Italian angels
Logo Doorway
Logo Anaxago
Logo I&I prague
Les business angels des grandes écoles
institut Marie Curie
Gustave Roussy
Centre de lutte contre le cancer
Sorbonne université

Our partners